Janssen Presents New Long-term Tremfya Data

Date : 10/17/2019 @ 9:09PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 141.38  0.04 (0.03%) @ 10:41PM
After Hours
Last Trade
Last $ 141.38 ◊ 0.00 (0.00%)

Janssen Presents New Long-term Tremfya Data

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

2 Months : From Oct 2019 to Dec 2019

Click Here for more Johnson and Johnson Charts.
   By Stephen Nakrosis 

The Janssen Pharmaceutical Companies of Johnson & Johnson presented long-term data from its Phase 3 VOYAGE 1 clinical trial of Tremfya, a treatment for adult patients with moderate to severe plaque psoriasis.

The data, being presented at the 39th Fall Clinical Dermatology Conference, studied patients receiving Tremfya, or guselkumab, from a group initially randomized to Tremfya or to placebo with crossover to Tremfya at week 16. Janssen said 82% achieved at least a 90% improvement in the Psoriasis Area Severity Index.

At 204 weeks, patients receiving Tremfya continued to show maintained PASI 90 and an Investigator's Global Assessment score of cleared or minimal disease, the company said.


--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

October 17, 2019 16:54 ET (20:54 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.